790677-27-9

Basic information

• Product Name: 1-(5-Aminoindolin-1-Yl)-2,2,2-Trifluoroethanone
• Synonyms: 1-(5-Aminoindolin-1-Yl)-2,2,2-Trifluoroethanone;1-(5-Aminoindolin-1-Yl)-2,2,2-Trifluoroethanone(WX602207)
• CAS NO: 790677-27-9
• Molecular Formula: C10H9F3N2O
• Molecular Weight: 230.1864696
• Mol File: 790677-27-9.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-(5-Aminoindolin-1-Yl)-2,2,2-Trifluoroethanone(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(5-Aminoindolin-1-Yl)-2,2,2-Trifluoroethanone(790677-27-9)
• EPA Substance Registry System: 1-(5-Aminoindolin-1-Yl)-2,2,2-Trifluoroethanone(790677-27-9)

Safety Data

• Hazardous Substances Data: 790677-27-9(Hazardous Substances Data)

Upstream product

• 32692-19-6 5-nitro-2,3-dihydro-1H-indole 
• 790677-11-1 2,2,2-trifluoro-1-(5-nitro-2,3-dihydro-indol-1-yl)-ethanone 

Relevant articles and documents

Luciferase substrates, and preparation method and application thereof

The invention provides luciferase substrates, and a preparation method and application thereof, belonging to the technical field of luciferase substrate preparation. The luciferase substrates have a structural formula as described in the specification. In the structural formula, R is hydrogen or deuterium. The luciferase substrates provided by the invention have the advantages of good selectivity,high sensitivity, low detection line, good biocompatibility and the like; and further studies prove that d2-cycluc is higher in bioluminescence intensity and longer in bioluminescence time in vitro,in cells and in vivo compared with cycluc, and the two luciferase substrates have good concentration dependence. The preparation method for the luciferase substrates in the inventions simple in process, high in operability and relatively low in cost, and thus has a good practical application value.

ENZYME MODULATORS AND TREATMENTS

Novel compounds and methods of using those compounds for the treatment of inflammatory conditions, hyperproliferative diseases, cancer, and diseases characterized by hypervascularization are provided. In a preferred embodiment, modulation of the activation state of p38 kinase protein ab1 kinase protein, bcr-ab1 kinase protein, braf kinase protein, VEGFR kinase protein, or PDGFR kinase protein comprises the step of contacting said kinase protein with the novel compounds.